Ranitidine Hydrochloride | CAS#66357-59-3 | Histamine H2-Receptor Antagonist

MedKoo Cat#: 318651 | Name: Ranitidine Hydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ranitidine hydrochloride is a histamine H2-receptor antagonist used in the treatment of gastrointestinal lesions due to excessive gastric acid secretion.

Chemical Structure

Ranitidine Hydrochloride

CAS#66357-59-3 (HCl)

Theoretical Analysis

MedKoo Cat#: 318651

Name: Ranitidine Hydrochloride

CAS#: 66357-59-3 (HCl)

Chemical Formula: C13H23ClN4O3S

Exact Mass: 350.1179

Molecular Weight: 350.86

Elemental Analysis: C, 44.50; H, 6.61; Cl, 10.10; N, 15.97; O, 13.68; S, 9.14

Price and Availability

Size	Price	Availability
1g	USD 150.00	Ready to ship
2g	USD 225.00	Ready to ship
5g	USD 350.00	Ready to ship
10g	USD 550.00	Ready to ship
20g	USD 750.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

66357-35-5 (free base) 66357-59-3 (HCl) 71130-06-8 (HCl) 128345-62-0 (bismuth citrate)

Synonym

Ranitidine Hydrochloride; ZANTAC; Tanidina; Toriol; Fendibina; Gastridina; Sostril; Zantic; Ranisen; Ranitidine HCl;

IUPAC/Chemical Name

(E)-N-(2-(((5-((dimethylamino)methyl)furan-2-yl)methyl)thio)ethyl)-N'-methyl-2-nitroethene-1,1-diamine hydrochloride

InChi Key

GGWBHVILAJZWKJ-KJEVSKRMSA-N

InChi Code

InChI=1S/C13H22N4O3S.ClH/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3;/h4-5,9,14-15H,6-8,10H2,1-3H3;1H/b13-9+;

SMILES Code

CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot# C21B06B11

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Ranitidine hydrochloride is a histamine H2-receptor antagonist with an IC50 of 3.3 μM that inhibits gastric secretion, CYP2C19, and CYP2C9.

In vitro activity:

In the current study, the ability of the widely used selective H2 antagonist ranitidine to modify key myeloid populations in the context of breast tumors was determined.Some breast cancer cells as well as normal breast tissue can express H2 receptors (for a review see ref. 8). Neither H1 nor H2 receptor antagonists had a direct effect on 4T1 cell proliferation or ability to migrate in vitro (Fig. S2). E0771 cells were similarly unaffected by histamine receptor antagonist treatment in vitro (data not shown). In keeping with these findings, neither 4T1 cells nor E0771 cells expressed H1 or H2 receptors (Fig. S3). These findings confirmed that H2 antagonists are not directly affecting the tumor cells via H2 receptors. Reference: Oncoimmunology. 2016 Jul; 5(7): e1151591. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006904/

In vivo activity:

To determine whether the effect of ranitidine on antibody responses was tumor specific, an OVA-Alum immunization and boost protocol was utilized to determine whether ranitidine altered OVA-specific antibody responses. ELISA results revealed that ranitidinetreated mice had higher titers of OVA-specific IgG1 and IgG2a compared with mice that were immunized without ranitidine treatment (Figures 4A,B). However, when the B16.F10-OVA melanoma model was used, there was no OVA-specific IgG1 and IgG2a antibody production observed (Figures4C,D). This suggests that while ranitidine is able to increase antibody production in an OVA immunization model and in the E0771 breast cancer model it does not have this effect in all tumor models, where there may be other immunosuppressive elements that ranitidine does not alter . cAMP release. Reference: Front Immunol. 2018; 9: 1894. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104125/

	Solvent	mg/mL	mM
Solubility
	DMSO	1.0	2.90
	H2O	1.8	5.10

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 350.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Butt AI, Khan BT, Khan A, Khan QU. Ranitidine Can Potentiate The Prokinetic Effect Of Itopride At Low Doses- An In Vitro Study. J Ayub Med Coll Abbottabad. 2017 Oct-Dec;29(4):554-558. PMID: 29330976. 2. Vila-Leahey A, Oldford SA, Marignani PA, Wang J, Haidl ID, Marshall JS. Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice. Oncoimmunology. 2016 Mar 10;5(7):e1151591. doi: 10.1080/2162402X.2016.1151591. PMID: 27622015; PMCID: PMC5006904. 3. Shi H, Yang X, Zhao H, Zhang S, Zu J, Zhang W, Shen X, Cui G, Hua F, Yan C. Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats. Neuropsychiatr Dis Treat. 2015 May 27;11:1331-7. doi: 10.2147/NDT.S80174. PMID: 26064051; PMCID: PMC4455849. 4. Rogers D, Vila-Leahey A, Pessôa AC, Oldford S, Marignani PA, Marshall JS. Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response. Front Immunol. 2018 Aug 15;9:1894. doi: 10.3389/fimmu.2018.01894. PMID: 30158936; PMCID: PMC6104125.

In vitro protocol:

In vivo protocol:

1. Shi H, Yang X, Zhao H, Zhang S, Zu J, Zhang W, Shen X, Cui G, Hua F, Yan C. Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats. Neuropsychiatr Dis Treat. 2015 May 27;11:1331-7. doi: 10.2147/NDT.S80174. PMID: 26064051; PMCID: PMC4455849. 2. Rogers D, Vila-Leahey A, Pessôa AC, Oldford S, Marignani PA, Marshall JS. Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response. Front Immunol. 2018 Aug 15;9:1894. doi: 10.3389/fimmu.2018.01894. PMID: 30158936; PMCID: PMC6104125.

1: Yusif RM, Abu Hashim II, Mohamed EA, El Rakhawy MM. Investigation and Evaluation of an in Situ Interpolymer Complex of Carbopol with Polyvinylpyrrolidone as a Matrix for Gastroretentive Tablets of Ranitidine Hydrochloride. Chem Pharm Bull (Tokyo). 2016;64(1):42-51. doi: 10.1248/cpb.c15-00620. PubMed PMID: 26726743. 2: Meani R, Nixon R. Allergic contact dermatitis caused by ranitidine hydrochloride in a veterinary product. Contact Dermatitis. 2015 Aug;73(2):125-6. doi: 10.1111/cod.12404. Epub 2015 Apr 19. PubMed PMID: 25891273. 3: Abduljabbar HN, Badr-Eldin SM, Aldawsari HM. Gastroretentive Ranitidine Hydrochloride Tablets with Combined Floating and Bioadhesive Properties: Factorial Design Analysis, In Vitro Evaluation and In Vivo Abdominal X-Ray Imaging. Curr Drug Deliv. 2015;12(5):578-90. PubMed PMID: 26051347. 4: Dhankar V, Garg G, Dhamija K, Awasthi R. Preparation, characterization and evaluation of ranitidine hydrochloride-loaded mucoadhesive microspheres. Polim Med. 2014 Apr-Jun;44(2):75-81. PubMed PMID: 24967779. 5: Khomane KS, Bansal AK. Effect of particle size on in-die and out-of-die compaction behavior of ranitidine hydrochloride polymorphs. AAPS PharmSciTech. 2013 Sep;14(3):1169-77. doi: 10.1208/s12249-013-0008-4. Epub 2013 Jul 30. PubMed PMID: 23897036; PubMed Central PMCID: PMC3755166. 6: Chauhan MS, Kumar A, Pathak K. Osmotically regulated floating asymmetric membrane capsule for controlled site-specific delivery of ranitidine hydrochloride: optimization by central composite design. AAPS PharmSciTech. 2012 Dec;13(4):1492-501. doi: 10.1208/s12249-012-9870-8. Epub 2012 Oct 27. PubMed PMID: 23104305; PubMed Central PMCID: PMC3513454. 7: Gharti K, Thapa P, Budhathoki U, Bhargava A. Formulation and in vitro evaluation of floating tablets of hydroxypropyl methylcellulose and polyethylene oxide using ranitidine hydrochloride as a model drug. J Young Pharm. 2012 Oct;4(4):201-8. doi: 10.4103/0975-1483.104363. PubMed PMID: 23493037; PubMed Central PMCID: PMC3573371. 8: Sadighi A, Ostad SN, Rezayat SM, Foroutan M, Faramarzi MA, Dorkoosh FA. Mathematical modelling of the transport of hydroxypropyl-β-cyclodextrin inclusion complexes of ranitidine hydrochloride and furosemide loaded chitosan nanoparticles across a Caco-2 cell monolayer. Int J Pharm. 2012 Jan 17;422(1-2):479-88. doi: 10.1016/j.ijpharm.2011.11.016. Epub 2011 Nov 11. PubMed PMID: 22101294. 9: Kotagale NR, Parkhe AP, Jumde AB, Khandelwal HM, Umekar MJ. Ranitidine Hydrochloride-loaded Ethyl Cellulose and Eudragit RS 100 Buoyant Microspheres: Effect of pH Modifiers. Indian J Pharm Sci. 2011 Nov;73(6):626-33. doi: 10.4103/0250-474X.100236. PubMed PMID: 23112396; PubMed Central PMCID: PMC3480747. 10: Córdoba S, Martínez-Morán C, García-Donoso C, Borbujo J, Gandolfo-Cano M. Non-occupational allergic contact dermatitis from pyridoxine hydrochloride and ranitidine hydrochloride. Dermatitis. 2011 Jul-Aug;22(4):236-7. PubMed PMID: 21781646. 11: Gore AH, Mote US, Tele SS, Anbhule PV, Rath MC, Patil SR, Kolekar GB. A novel method for ranitidine hydrochloride determination in aqueous solution based on fluorescence quenching of functionalised CdS QDs through photoinduced charge transfer process: spectroscopic approach. Analyst. 2011 Jun 21;136(12):2606-12. doi: 10.1039/c0an01038c. Epub 2011 Apr 26. PubMed PMID: 21519628. 12: Sharma N, Rao SS, Kumar ND, Reddy PS, Reddy AM. A validated stability-indicating liquid-chromatographic method for ranitidine hydrochloride in liquid oral dosage form. Sci Pharm. 2011 Jun;79(2):309-22. doi: 10.3797/scipharm.1101-06. Epub 2011 Feb 12. PubMed PMID: 21773068; PubMed Central PMCID: PMC3134857. 13: Sokół A, Karpińska J, Talecka R, Starczewska B. Quantification of ranitidine hydrochloride in the presence of its decomposition product by spectrophotometric methods. Application for kinetic study. Acta Pol Pharm. 2011 Mar-Apr;68(2):169-77. PubMed PMID: 21485289. 14: Chabukswar A, Jagdale S, Kuchekar B, Joshi V, Deshmukh G, Kothawade H, Kuckekar A, Lokhande P. Six sigma: process of understanding the control and capability of ranitidine hydrochloride tablet. J Young Pharm. 2011 Jan;3(1):15-25. doi: 10.4103/0975-1483.76415. PubMed PMID: 21607050; PubMed Central PMCID: PMC3094555. 15: Jain S, Srinath M, Narendra C, Reddy S, Sindhu A. Development of a floating dosage form of ranitidine hydrochloride by statistical optimization technique. J Young Pharm. 2010 Oct;2(4):342-9. doi: 10.4103/0975-1483.71619. PubMed PMID: 21264091; PubMed Central PMCID: PMC3019370. 16: Shen S, Yun D, Li F. [Determination of dichloromethane and trichloromethane residues in ranitidine hydrochloride by headspace liquid phase microextraction coupled with gas chromatography]. Se Pu. 2009 Nov;27(6):845-8. Chinese. PubMed PMID: 20352943. 17: Khan S, Giradkar P, Yeole P. Formulation design of ranitidine hydrochloride to reduce its moisture absorption characteristics. PDA J Pharm Sci Technol. 2009 May-Jun;63(3):226-33. PubMed PMID: 20069795. 18: Kumar P, Singh S, Mishra B. Floating osmotic drug delivery system of ranitidine hydrochloride: development and evaluation--a technical note. AAPS PharmSciTech. 2008;9(2):480-5. doi: 10.1208/s12249-008-9065-5. Epub 2008 Mar 18. PubMed PMID: 18431658; PubMed Central PMCID: PMC2976918. 19: Uzunović A, Vranić E. Effect of magnesium stearate concentration on dissolution properties of ranitidine hydrochloride coated tablets. Bosn J Basic Med Sci. 2007 Aug;7(3):279-83. PubMed PMID: 17848158. 20: Jain AK, Jain SK, Yadav A, Agrawal GP. Controlled release calcium silicate based floating granular delivery system of ranitidine hydrochloride. Curr Drug Deliv. 2006 Oct;3(4):367-72. PubMed PMID: 17076638.